**SOC FOR ALK+ RESECTED NSCLC¹**

Superior DFS vs. chemotherapy, sustained for 4 years^1*

DFS in Stage II–IIIA^†

DFS in Stage IB–IIIA (ITT)^†

A clinically meaningful CNS DFS benefit maintained for 4 years^1*

CNS DFS in Stage IB–IIIA^†

ALINA study design

*Median follow-up (ITT): ALECENSA: 48.0 months; chemotherapy: 47.4 months.¹ †Per UICC/AJCC 7th edition.¹AJCC, American Joint Committee on Cancer; ALK, anaplastic lymphoma kinase; CI, confidence interval; CNS, central nervous system; DFS, disease-free survival; HR, hazard ratio; ITT, intent-to-treat; NE, non-estimable; NSCLC, non-small cell lung cancer; SoC, standard of care; UICC, Union for International Cancer Control.

1. Dziadziuszko R, et al. Updated results from the Phase III ALINA study of adjuvant alectinib vs chemotherapy in patients with early stage ALK+ non-small cell lung cancer (NSCLC). ESMO. 17–21 October 2025. Berlin, Germany.

This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration, or usage in the country of your origin.

FOR HEALTHCARE PROFESSIONALS

Leaving website

**SOC FOR ALK+ RESECTED NSCLC¹**

DFS in Stage II–IIIA^†

DFS in Stage II–IIIA^†

DFS in Stage IB–IIIA (ITT)^†

CNS DFS in Stage IB–IIIA^†

CNS DFS in Stage IB–IIIA^†

Discover

Explore

FOR HEALTHCARE PROFESSIONALS

Leaving website

SOC FOR ALK+ RESECTED NSCLC1

DFS in Stage II–IIIA†

DFS in Stage II–IIIA†

DFS in Stage IB–IIIA (ITT)†

CNS DFS in Stage IB–IIIA†

CNS DFS in Stage IB–IIIA†

Discover

Explore

**SOC FOR ALK+ RESECTED NSCLC¹**

DFS in Stage II–IIIA^†

DFS in Stage II–IIIA^†

DFS in Stage IB–IIIA (ITT)^†

CNS DFS in Stage IB–IIIA^†

CNS DFS in Stage IB–IIIA^†